Literature DB >> 22718548

DNA hypermethylation and 1p Loss silence NHE-1 in oligodendroglioma.

Michael D Blough1, Mohammad Al-Najjar, Charles Chesnelong, Carmen E Binding, Alexandra D Rogers, H Artee Luchman, John J Kelly, Larry Fliegel, Olena Morozova, Stephen Yip, Marco Marra, Samuel Weiss, Jennifer A Chan, J Gregory Cairncross.   

Abstract

Oligodendroglioma is characterized by mutations of IDH and CIC, 1p/19q loss, and slow growth. We found that NHE-1 on 1p is silenced in oligodendrogliomas secondary to IDH-associated hypermethylation and 1p allelic loss. Silencing lowers intracellular pH and attenuates acid load recovery in oligodendroglioma cells. Others have shown that rapid tumor growth cannot occur without NHE-1-mediated neutralization of the acidosis generated by the Warburg glycolytic shift. Our findings show for the first time that the pH regulator NHE-1 can be silenced in a human cancer and also suggest that pH deregulation may contribute to the distinctive biology of human oligodendroglioma.
Copyright © 2012 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22718548     DOI: 10.1002/ana.23610

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  14 in total

1.  Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.

Authors:  Katherine S Panageas; Anne S Reiner; Fabio M Iwamoto; Timothy F Cloughesy; Kenneth D Aldape; Andreana L Rivera; April F Eichler; David N Louis; Nina A Paleologos; Barbara J Fisher; Lynn S Ashby; J Gregory Cairncross; Gloria B Roldán Urgoiti; Patrick Y Wen; Keith L Ligon; David Schiff; H Ian Robins; Brandon G Rocque; Marc C Chamberlain; Warren P Mason; Susan A Weaver; Richard M Green; Francois G Kamar; Lauren E Abrey; Lisa M DeAngelis; Suresh C Jhanwar; Marc K Rosenblum; Andrew B Lassman
Journal:  Neuro Oncol       Date:  2014-07-04       Impact factor: 12.300

2.  Lactate dehydrogenase A silencing in IDH mutant gliomas.

Authors:  Charles Chesnelong; Myriam M Chaumeil; Michael D Blough; Mohammad Al-Najjar; Owen D Stechishin; Jennifer A Chan; Russell O Pieper; Sabrina M Ronen; Samuel Weiss; H Artee Luchman; J Gregory Cairncross
Journal:  Neuro Oncol       Date:  2013-12-22       Impact factor: 12.300

3.  Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

Authors:  J Gregory Cairncross; Meihua Wang; Robert B Jenkins; Edward G Shaw; Caterina Giannini; David G Brachman; Jan C Buckner; Karen L Fink; Luis Souhami; Normand J Laperriere; Jason T Huse; Minesh P Mehta; Walter J Curran
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

4.  Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma.

Authors:  Myriam M Chaumeil; Peder E Z Larson; Sarah M Woods; Larry Cai; Pia Eriksson; Aaron E Robinson; Janine M Lupo; Daniel B Vigneron; Sarah J Nelson; Russell O Pieper; Joanna J Phillips; Sabrina M Ronen
Journal:  Cancer Res       Date:  2014-05-29       Impact factor: 12.701

Review 5.  Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.

Authors:  Daniel P Cahill; David N Louis; John Gregory Cairncross
Journal:  CNS Oncol       Date:  2015-11-06

Review 6.  Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop.

Authors:  Jason T Huse; Max Wallace; Kenneth D Aldape; Mitchel S Berger; Chetan Bettegowda; Daniel J Brat; Daniel P Cahill; Timothy Cloughesy; Daphne A Haas-Kogan; Marco Marra; C Ryan Miller; Sarah J Nelson; Sofie R Salama; Riccardo Soffietti; Patrick Y Wen; Stephen Yip; Katharine Yen; Joseph F Costello; Susan Chang
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

7.  Quantitative sodium imaging and gliomas: a feasibility study.

Authors:  Lucidio P Nunes Neto; Guillaume Madelin; Terlika Pandit Sood; Chih-Chun Wu; Douglas Kondziolka; Dimitris Placantonakis; John G Golfinos; Andrew Chi; Rajan Jain
Journal:  Neuroradiology       Date:  2018-06-03       Impact factor: 2.804

Review 8.  From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.

Authors:  Xueyuan Sun; Sevin Turcan
Journal:  Cells       Date:  2021-05-17       Impact factor: 6.600

Review 9.  Involvement of tumor acidification in brain cancer pathophysiology.

Authors:  Avinash Honasoge; Harald Sontheimer
Journal:  Front Physiol       Date:  2013-11-01       Impact factor: 4.566

10.  Downregulation of TES by hypermethylation in glioblastoma reduces cell apoptosis and predicts poor clinical outcome.

Authors:  Yu Bai; Quan-Geng Zhang; Xin-Hua Wang
Journal:  Eur J Med Res       Date:  2014-12-11       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.